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GWAS for systemic sclerosis identifies multiple
risk loci and highlights fibrotic and vasculopathy
pathways
Elena López-Isac et al.#
Systemic sclerosis (SSc) is an autoimmune disease that shows one of the highest mortality
rates among rheumatic diseases. We perform a large genome-wide association study
(GWAS), and meta-analysis with previous GWASs, in 26,679 individuals and identify 27
independent genome-wide associated signals, including 13 new risk loci. The novel asso-
ciations nearly double the number of genome-wide hits reported for SSc thus far. We define
95% credible sets of less than 5 likely causal variants in 12 loci. Additionally, we identify
specific SSc subtype-associated signals. Functional analysis of high-priority variants shows
the potential function of SSc signals, with the identification of 43 robust target genes through
HiChIP. Our results point towards molecular pathways potentially involved in vasculopathy
and fibrosis, two main hallmarks in SSc, and highlight the spectrum of critical cell types for
the disease. This work supports a better understanding of the genetic basis of SSc and
provides directions for future functional experiments.
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Rheumatic diseases are one of the main causes of physicaldisability of non-mental origin in the Western worldaccording to the World Health Organization. Rheumatic
diseases have a marked impact on the quality of life of patients.
Among them, systemic sclerosis (SSc) has one of the highest
mortality rates1. SSc is a chronic autoimmune disease (AD) that
affects the connective tissue, with very heterogeneous clinical
manifestations. The pathogenesis of the disease involves extensive
fibrosis of the skin and internal organs, vascular damage, and
immune imbalance, including autoantibody production2,3. Lung
involvement—both pulmonary hypertension and/or pulmonary
fibrosis—is the leading cause of death4.
As most ADs, SSc has a complex genetic component and its
etiology is poorly understood. Genome-wide association studies
(GWASs) have been successful in the identification of thousands
of genetic variants associated with the susceptibility of complex
traits. Moreover, GWASs provide invaluable information on
disease aetiopathogenesis and contribute to drug discovery and
repurposing5,6. Several GWASs of SSc have been published,
which greatly contributed to the understanding of SSc patho-
genesis, and pointed out to relevant pathways for the disease, such
as the interferon pathway, the interleukin 12 pathway, and
apoptosis7–12. Nonetheless, the rate of discovery of previous
studies was limited owing to the relatively small sample sizes of
the study cohorts.
To continue unraveling the partially known genetic back-
ground of SSc, we perform a powerful meta-GWAS in European
population that includes ~ 10,000 patients. We also hypothesize
that an integrative approach combining all SSc association sig-
nals, fine-mapping, and the identification of target genes based on
chromatin contacts would provide further insights into the biol-
ogy of the disease.
Results
Twenty-seven signals independently associated with SSc. We
performed genome-wide association analyses in 14 independent
European cohorts comprising a total of 26,679 individuals (9,095
SSc patients and 17,584 healthy controls). Nine out of the 14 SSc
GWAS cohorts were so far unreported, whereas 5 had been
previously published7,8 (Supplementary Data 1). After correcting
for sex and the first five principal components (PCs) (Methods),
we did not observe genomic inflation in any of the independent
GWAS cohorts, with the exception of the Italian cohort, which
remained with residual inflation (Supplementary Data 1 and
Supplementary Fig. 1). Overall, the meta-analysis showed a
genomic inflation factor (λ) of 1.10, with a rescaled λ1000 of 1.008
for an equivalent study of 1000 cases/1000 controls (Supple-
mentary Data 1).
We undertook an inverse variance-weighted meta-analysis with
a high-density genotyped and imputed SNP panel (4.72 million
SNPs) to combine all independent GWASs. We considered all the
SNPs that were shared by at least two data sets to avoid SNP data
loss. This approach yielded 431 significantly associated SNPs
(association test p value ≤ 5 × 10−8) excluding the well-known
HLA region. Significant signals involved 23 genomic regions, of
which 13 were new genome-wide significant loci for SSc and 10
corresponded to previously reported GWAS signals (Table 1,
Fig. 1).
The presence of independent signals in the genomic regions
that showed significant associations was investigated by stepwise
conditional analysis using summary statistics from the meta-
analysis (Methods). Four genomic regions—TNFSF4 (1q25.1),
STAT4 (2q32.2-q32.3), DNASE1L3 (3p14.3), and IRF5-TNPO3
(7q32.1)—showed additional significant signals after conditioning
on the lead SNP of each locus (conditional association test p value
(Pcond) < 5 × 10−6) (Table 1, Fig. 1, Supplementary Fig. 2).
Hence, a total of 27 independent signals associated with SSc were
identified.
The two independent signals identified in the DNASE1L3
genomic region (3p14.3) (rs4076852, rs7355798) were intronic
variants at PXK and FLNB, respectively. PXK-rs4076852 is in
high linkage disequilibrium (LD) with PXK-rs2176082 (r2=
0.92), which was reported to be associated with SSc in Martin
et al.13 However, two Immunochip studies conducted by Mayes
et al.9 and Zochling et al.12 showed that the primary association
in this genomic region was with the nonsynonymous SNP
DNASE1L3-rs35677470 (R206C), not present in our SNP panel.
Mayes et al.9 showed that the PXK-rs2176082 association was
dependent on the rs35677470 (R206C). Therefore, although we
could not analyze the dependence in our GWAS data, we
presumed that PXK-rs4076852 signal was also dependent on
DNASE1L3-rs35677470 on the basis of previous evidence.
Regarding the intronic signal in FLNB (rs7355798), we could
not estimate whether it was dependent on DNASE1L3-
rs35677470 or not. However, given its role in vascular injury
repair14, FLNB may be an interesting SSc locus and should be the
object of future research. In the case of the STAT4 genomic region
(2q32.2-q32.3), we observed three independent signals, of which
the third was an intronic variant at NAB1 (rs16832798). This
finding—added to further functional evidence provided below—
revealed NAB1 as a new SSc risk locus. We also observed that the
genome-wide signal in GSDMB (17q21.1; rs883770) was inde-
pendent (Pcond= 1.27 × 10−7) from the recently reported signal
at GSDMA (rs3894194), which is located in the same genomic
region10.
Fine-mapping of SSc-associated loci in a Bayesian framework.
The identification of the causal SNPs driving the association
signals remains an open question after completion of a GWAS.
To address this question, Bayesian fine-mapping was performed
to define 95% credible sets (the smallest set of variants that
summed together at least a 95% probability of including the likely
causal variant) in each of the independently associated loci (the
two independent signals in IRF5-TNPO3 were excluded as fine-
mapping was not feasible). To improve SNP prioritization accu-
racy, the probabilistic method integrated association strength
with functional annotation data (Methods). Eighteen (72%) and
12 (48%) out of the 25 loci were fine-mapped to ≤10 and to <5
plausible causal variants, respectively (Table 2, Supplementary
Data 2). In six loci, the 95% credible set comprised a single
variant (ARHGAP31, BLK, CD247, TNIP1, CSK, STAT4-a), and
for four others the credible set contained two SNPs (DGKQ,
NUP85-GRB2, STAT4-b, IL12RB1). Moreover, in 64% of the
credible sets, the index SNP showed the maximum posterior
probability (PPmax) of being causal. The SNPs with PPmax were
intergenic, intronic, or noncoding RNA intronic (ncRNA intro-
nic) variants, although the remaining credible set SNPs involved
additional SNP categories, namely: UTR3′, downstream, exonic
synonymous, and exonic nonsynonymous (Table 2).
Functional annotation of SNPs from credible sets. Since most
of the likely causal variants were linked to regulatory functions
rather than affecting the function of proteins encoded by sur-
rounding genes, we further explored their regulatory effects. For
this purpose, we performed functional annotation of SNPs from
credible sets through eQTL analysis (Methods). In addition, we
explored overlap with histone marks of active promoters and
active enhancers (H3K9ac, H3K4me1, and H3K27ac) of cell types
relevant to the disease using data from the Roadmap Epigenomics
Project15 (Supplementary Table 1) (Methods).
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Supplementary Figure 3 summarizes the results of the functional
characterization of credible set SNPs. When the 95% credible set
was not well resolved (credible sets that contained > 15 likely causal
variants), we selected the SNP with PPmax and the index SNP. In the
case of IRF5-TNPO3, where the credible set was not feasible, we
selected the two independent signals identified at this locus. We
obtained a final reduced list of credible set SNPs containing a total
of 81 variants. As it can be observed in Supplementary Fig. 3, the
vast majority of the likely causal variants overlapped with promoter
and enhancer histone marks in the cell types interrogated. These
observations suggest that most of the genetic variations involved in
the susceptibility to SSc modulate transcriptional regulatory
mechanisms. In this regard, we found that 61 out of the 81
interrogated variants (75.31% of the 81 listed credible set SNPs)
represent eQTLs, thus altering gene expression in different tissues
and cell types (Supplementary Data 3). In fact, the credible set SNPs
were significantly enriched for eQTLs in blood and non-blood
tissues (odds ratio (OR)= 3.05, Fisher’s exact test P= 5.65 × 10−6;
OR= 1.61, Fisher’s exact test P= 4.48 × 10−2, respectively) (Sup-
plementary Table 2). Many SNPs were shown to impact the
expression of the closest gene (a priori candidate gene) (Supple-
mentary Data 3). In addition, we also found genetic variants
affecting the expression of a priori candidate genes and other genes.
However, some SNPs only showed eQTL signals for genes other
than the closest one. As an example, the SNP rs9884090—which is
an intronic variant at ARHGAP31—was found to alter the
expression of POGLUT1 and TIMMDC1 in several tissues
(Supplementary Data 3). These results highlight that assigning
association signals to the nearby gene is not always the most
appropriate strategy and the functional role of certain SSc signals
may expand to different target genes.
Five 95% credible sets comprised exonic nonsynonymous
variants or contained SNPs in high-to-moderate LD with exonic
nonsynonymous variants (r2 ≥ 0.8, r2 ≥ 0.6, respectively) (ARH-
GAP31, IRF7, GSDMB, NUP85-GRB2, and IL12RB1) (Supple-
mentary Fig. 3, Supplementary Data 4). However, based on SIFT
and PolyPhen, none of these exonic variants showed a clear
consensus to be deleterious16,17 (Supplementary Data 4).
Finally, we assessed pleiotropic effect of our signals by
determining whether the likely causal SNPs were also risk factors
for other diseases. The results showed extensive overlap especially
with other two ADs: systemic lupus erythematosus and primary
biliary cholangitis (Supplementary Data 5). These findings were
consistent with previous reports that identified shared risk loci for
SSc and other immune-mediated diseases11,13.
H3K27ac HiChIP in T cells expands and refines target genes.
As stated above, assigning disease-associated variants to the clo-
sest gene is not always an appropriate strategy to determine the
potential mechanistic effect of association signals. With the aim of
identifying the putative drivers of SSc association hits on the basis
of functional evidence, we performed an analysis of experimen-
tally derived high-resolution maps of enhancer-promoter inter-
actions generated by H3K27ac HiChIP experiments in human
CD4+ T cells18 (Methods).
HiChIP interactions were detected in 18 out of the 27 (66.67%)
independently associated loci, using the SNPs with PPmax as
anchor points (Table 3). Several intronic variants were linked to
the target gene promoter in which they are mapped. This was the
case of CD247-rs2056626, which showed a strong H3K27ac
HiChIP signal to the CD247 promoter (Fig. 2). Other relevant
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Fig. 1 Association signals for systemic sclerosis in a large meta-GWAS. aManhattan plot representing the meta-GWAS results. The −log10 of the p values
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signals in IRF5-TNPO3 for the global meta-analysis; association signals conditioned on the lead SNP (rs36073657), and conditioned on rs36073657 and the
secondary signal at the locus (rs12155080)
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-12760-y
4 NATURE COMMUNICATIONS |         (2019) 10:4955 | https://doi.org/10.1038/s41467-019-12760-y | www.nature.com/naturecommunications
examples of this type of interactions were found in IL12RB2 and
NFKB1. The intronic variants in STAT4, rs3821236 and
rs4853458, showed strong normalized HiChIP signal to STAT4
and STAT1 promoters (Fig. 2). We also observed HiChIP
contacts that linked intergenic SNPs to the closest genes. For
example, rs11117422, located ~40 kb downstream of IRF8
transcriptional start site, showed interactions with the promoter
region of IRF8 (Fig. 2). In addition, several other enhancer-
promoter interactions linked intronic and intergenic SNPs to
distant genes. In total, H3K27ac HiChIP signals nominated 155
target genes from 18 SSc likely causal variants (~8 genes per SNP
on average) (Table 3).
Subsequently, we further validated the functional relevance of
H3K27ac HiChIP results by investigating whether the explored
SNPs were eQTLs for the nominated target genes. Forty enhancer-
target gene relationships showed overlap with SSc eQTL genes
(eGenes) (OR= 10.1, Fisher’s exact test P= 2.92 × 10−19, Supple-
mentary Table 3). Although no eQTL to IRF8, STAT4, and
STAT1 signals were found, the enrichment of the HiChIP signal
observed at these loci (q value < 1e-60, Methods) over a global
background of distance-matched interactions, and the crucial role
of these genes in the immune response, provided evidence to
prioritize them as candidate genes. Remarkably, the third
independent association signal observed in the STAT4 genomic
region (2q32.2-q32.3)—mapped in a NAB1 intron—was linked to
NAB1 promoter by our H3K27ac HiChIP analysis. The
interaction was validated by an eQTL signal (Supplementary
Data 3). These results supported NAB1 as a new SSc risk locus.
In total, we provided strong evidence to nominate 43 genes as
robust SSc target genes in CD4+ T cells (Table 3). Interestingly,
some of them pinpointed to new mechanistic insights relevant for
the diseases (see Discussion).
Chromatin interaction analyses in other relevant cell types. It is
noteworthy that the epigenomic profiles are cell type spe-
cific19,20. Considering that the HiChIP analyses were performed
in CD4+ T cells, and that the pathogenesis of SSc is not only
mediated by T cells, we also explored chromatin interaction
maps derived from promoter capture Hi-C experiments in
additional immune cell types21,22 (Methods). These analyses
identified promoter interactions not observed in CD4+ T cells,
which targeted new genes (Table 3, Supplementary Data 6). For
example, we observed that the FLNB-intronic variant rs7355798
interacted with FLNB and PXK promoters in B cells and mac-
rophages. Moreover, some of the interactions observed with
H3K27ac HiChIP in CD4+ T cells were also found in other
immune cell types.
The functional relevance of the observed chromatin interac-
tions by promoter capture Hi-C analyses was also validated by
eQTLs analysis. In total, these analyses nominated 25 additional
target genes for SSc (Table 3).
Table 2 Posterior probabilities of systemic sclerosis fine-mapped loci
Chr Credible set locus SNPs
Cred. Set
Index SNP PP Index SNP PP Max PP Max Func.refgene
SNP PP Max
Func.refgene in the 95%
credible set
1 IL12RB2 6 rs3790566 0.195 rs3790567 0.321 Intronic Intronic
1 CD247 1 rs2056626 0.999 rs2056626 0.999 Intronic -
1 TNFSF4-
LOC100506023-PRDX6
6 rs2022449 0.659 rs2022449 0.659 ncRNA Intronic ncRNA_intronic
1 TNFSF4-
LOC100506023-PRDX6
43 rs1857066 0.046 rs11576547 0.265 ncRNA intronic ncRNA_intronic
2 NAB1 11 rs16832798 0.191 rs716254 0.242 Intronic Intronic; intergenic;
downstream
2 STAT4-a1 1 rs3821236 1.000 rs3821236 1.000 Intronic -
2 STAT4-b2 2 rs4853458 0.905 rs4853458 0.905 Intronic Intronic
3 FLNB-DNASE1L3-PXK 6 rs7355798 0.365 rs7355798 0.365 Intronic Intronic
3 FLNB-DNASE1L3-PXK 27 rs4076852 0.123 rs7653734 0.292 Intronic Intronic; intergenic
3 POGLUT1-TIMMDC1-
CD80-ARHGAP31
1 rs9884090 0.956 rs9884090 0.956 Intronic -
3 IL12A 23 rs589446 0.385 rs589446 0.385 ncRNA intronic ncRNA_intronic
4 DGKQ 2 rs11724804 0.793 rs11724804 0.793 Intronic Intronic
4 NFKB1 6 rs230534 0.200 rs230517 0.329 Intronic Intronic
5 TNIP1 1 rs3792783 0.999 rs3792783 0.999 Intronic -
6 ATG5 3 rs633724 0.588 rs633724 0.588 Intronic Intronic
8 FAM167A-BLK 1 rs2736340 1.000 rs2736340 1.000 Intergenic -
8 RAB2A-CHD7 80 rs685985 0.003 rs6987084 0.139 Intronic Intronic; UTR3; intergenic
11 CDHR5-IRF7 4 rs6598008 0.760 rs6598008 0.760 Intronic Intronic; exonic synonymous
SNV; UTR3; exonic
nonsynonymous
11 TSPAN32,CD81-AS1 20 rs2651804 0.184 rs2651804 0.184 Intergenic Intergenic
11 DDX6 7 rs11217020 0.021 rs10892286 0.775 Intronic Intronic; intergenic
15 CSK 1 rs1378942 0.993 rs1378942 0.993 Intronic -
16 IRF8 6 rs11117420 0.202 rs11117422 0.54 Intergenic Intergenic
17 IKZF3-GSDMB 17 rs883770 0.032 rs9303277 0.157 Intronic Intergenic; intronic; exonic
synonymous SNV; exonic
nonsynonymous
17 NUP85-GRB2 2 rs1005714 0.940 rs1005714 0.940 Intronic Intronic
19 IL12RB1 2 rs2305743 0.944 rs2305743 0.944 Intronic Intronic
Chr chromosome, PP posterior probability, SNP single-nucleotide polymorphism
1Name of the credible set that comprised the index SNP from STAT4 genomic region (2q32.2-q32.3)
2Name of the credible set that comprised the secondary association signal in STAT4 genomic region (2q32.2-q32.3)
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Candidate genes prioritized by DEPICT. In addition, we also
conducted gene prioritization by means of DEPICT (Data-driven
Expression-Prioritized Integration for Complex Traits) (http://
www.broadinstitute.org/mpg/depict/index.html), which pinpoints
the most likely candidate gene/s in associated loci based on
predicted gene functions23. Significant gene prioritization p values
were found in 19 of the 27 queried loci (Table 3, Supplementary
Data 7). Most of the prioritized genes were previously nominated
by the chromatin interaction analyses. In addition, this method
nominated TNFSF4, TMEM194B, FLNB-AS1, CD80, ARHGAP31,
C8orf14, TSPAN32, and MAST3.
Tissue-specific enrichment of SSc loci in epigenetic marks. The
majority of credible set SNPs overlapped with epigenetic marks
related to active regions (Supplementary Fig. 3). To quantify the
extent of this overlap, we investigated whether SSc associations
were non-randomly distributed in histone marks of active pro-
moters (H3K9ac, H3K4me2, H3K4me3, H3K4ac), active enhan-
cers (H3K27ac, H3K4me1, H2BK20ac), and active (or at least
accessible) genes (H3K79me1, H2BK15ac) across the 127 refer-
ence epigenomes available from the Roadmap Epigenomics
Consortium and the Encyclopedia of DNA Elements (ENCODE)
projects15,24. We used a nonparametric approach (GAR-
FIELD25,26) to compute ORs and estimate the significance of
functional enrichment at various GWAS p value cutoffs (5 × 10−6,
5 × 10−7, and 5 × 10−8) (Methods).
Our results showed 363 significant enrichments (p value <
1.25 × 10−4) in 59 out of the 127 cell and tissue types analyzed
(Fig. 3, Supplementary Data 8). Most of the significant
enrichments were found in immune cells. SSc-associated variants
displayed the most significant enrichments in H2BK15ac and
H2BK20ac marks in the GM12878 lymphoblastoid cell line
(OR= 37.33, enrichment p value (Penr)= 4.84 × 10−14;
OR= 12.79, Penr= 2.40 × 10−10, respectively), followed by
H3K79me1 in primary Natural Killer (NK) cells (BLD.CD56.
PC) (OR= 12.23, Penr= 5.73 × 10−09) and primary T cells (BLD.
CD3.PPC) (OR= 12.58, Penr= 9.78 × 10−09). The spleen also
showed a strong functional enrichment in H2BK15ac
(OR= 14.69, Penr= 9.81 × 10−09). There were significant enrich-
ments of associations with SSc within H3K27ac, H3K4me1,
H3K4me2, and H3K9ac marks—among others—of several CD4+
T cells (T helper, T regulatory, etc), CD8+ T cells, primary B cells,
monocytes, primary neutrophils, and thymus (Fig. 3, Supple-
mentary Data 8). Moreover, the SSc association signals showed
different epigenetic enrichment patterns in non-immune cell/
tissue types, such as lung, fibroblasts, chondrocytes, keratinocytes,
osteoblasts, intestinal mucosa, and esophagus, among others
(Fig. 3, Supplementary Data 8).
Interestingly, our large panel of reference epigenomes allowed
us to identify cell type specific patterns of enrichment. This
specificity was especially relevant for some tissue/cell types that
showed enrichment for a single histone mark. For example,
dermal fibroblast primary cells (SKIN.NHDFAD) only showed
significant enrichment for H3K4me2 (OR= 7.91, Penr= 6.54 ×
10−6).
Specific patterns of associations for the main SSc subtypes. We
performed GWAS stratified analyses considering the main SSc
clinical subtypes (limited cutaneous SSc (lcSSc) or diffuse cuta-
neous SSc (dcSSc)) and autoantibody status according to the
presence of anticentromere (ACA), antitopoisomerase (ATA),
and anti-RNA polymerase III (ARA) autoantibodies (Supple-
mentary Table 4) (Methods).
A total of 18 and 5 non-HLA significant signals were identified
for lcSSc and dcSSc, respectively, representing 15 new genome-
wide significant signals for lcSSc and 3 for dcSSc (Supplementary
Data 9). Among the associations, there were loci that yielded
stronger associations and larger effect size in the subtype analyses
than in the global meta-analysis; all despite the reduction of the
sample and, consequently, of statistical power. To assess whether
the more powerful genetic signals were randomly observed, we
performed 10,000 permutation analyses (Methods) and computed
empirical p values (p*) taking into account the proportion of
permuted genetic signals that were at least as extreme as the
observed signals. As an example, DNASE1L3 genomic region
(3p14.3, rs7652027) was associated with the global disease with an
OR of 1.15, whereas the OR observed for the lcSSc subtype was
1.20. Permutation analysis showed significant empirical p value
(p*= 1.9 × 10−3) for DNASE1L3-rs7652027 thus confirming a
larger effect of this risk factor in lcSSc patients (Supplementary
Data 9, Supplementary Fig. 4).
Remarkably, we observed two subtype-specific signals that did
not show statistical significance in the global analysis. In the case
of lcSSc, there was a significant association in the MERTK
genomic region (2q13) (association test p value= 1.04 × 10−08,
OR= 1.15) that was not significant in the global meta-analysis
(association test p value= 3.49 × 10−05, OR= 1.09) nor in dcSSc
sub-analysis (association test p value= 0.503, OR= 1.02) (Sup-
plementary Data 9 and Supplementary Fig. 5) (Supplementary
Fig. 4, p*= 1.0 × 10−4). MERTK is a tyrosine kinase member of
the MER/AXL/TYRO3 receptor kinase family that is associated
with multiple sclerosis27 and hepatitis C-induced liver fibrosis28.
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Moreover, the associated variant (rs3761700), affects the expres-
sion of MERTK in whole blood (p value= 1.22 × 10−35).
Regarding dcSSc, we found an association signal in the
ANKRD12 genomic region (18p11.22) (association test p
value= 3.97 × 10−08, OR= 1.22). This locus did not show
significant associations in the global meta-analysis (association
test p value= 2.30 × 10−05, OR= 1.10) nor in the lcSSc subtype
(association test p value= 0.034, OR= 1.06) (Supplementary
Data 9 and Supplementary Fig. 5) (Supplementary Fig. 4,
p*= 4.0 × 10−4). ANKRD12 encodes a member of the ankyrin
repeats-containing cofactor family involved in the modulation of
gene transcription. The associated variant—rs4798783—is an
eQTL for TWSG1 (p value= 6.44 × 10−06) in transformed
fibroblasts. Interestingly, TWSG1 enhances TGF-beta signaling
(which profibrotic role is well-known) in activated T lympho-
cytes29. These findings and the specific association with dcSSc are
of utmost importance, given the more aggressive and rapidly
progressing fibrosis observed in this clinical subtype2,3.
When data were stratified by patients positive for ACA, nine
genome-wide significant signals were found, of which two had
been previously reported (IRF5-TNPO3, and DNASE1L3) and
seven were novel associations (Supplementary Data 10). Notably,
the locus CDHR5-IRF7 was strongly associated with this autoanti-
body presentation (association test p value= 5.32 × 10−09,
OR= 0.73) and showed stronger effect as compared to the global
meta-analysis (association test p value= 1.97 × 10−08, OR= 0.80)
(Supplementary Fig. 4, p*= 2.1 × 10−3). Regarding the ATA-
positive subgroup, we replicated the previously reported associa-
tion with IRF5-TNPO3 (Supplementary Data 10)30. Finally, in the
case of the RNA pol III-positive SSc patients, we did not observe
any signal at the genome-wide significance level outside the HLA
region. Nonetheless, we found suggestive associations in
FAM167A-BLK, GUSBP1-CDH12, and STEAP2 (Supplementary
Data 10).
Overall, our findings highlights how performing GWASs in
more homogeneous group of patients can increase the success of
case–control studies by improving association strengths, thus
avoiding reduction of statistical power owing to phenotypic
heterogeneity31. Moreover, consistent with previous studies,
suggesting genetic differences in the susceptibility to SSc
subtypes9,32 the identification of specific patterns of association
in each SSc subphenotype emphasizes the importance of
classification biomarkers to predict more accurately the best
therapeutic approach in each group of patients.
Drug target enrichment analysis. The advantage of using human
genetic evidence in drug discovery and repurposing has been
comprehensively addressed in the last years5,6. In this line, we
assessed whether any of the 78 SSc target genes identified in the
present study (genes from the last three columns of Table 3)
encode proteins that are drug targets in any phase of develop-
ment. Seven out of the 78 genes (9%) overlapped with pharma-
cological active targets (CD80, BLK, TNFSF4, IL12A, DRD4,
PSMD3, FDFT1) in the Open Targets Platform33 (Supplementary
Data 11). Among them, CD80 and BLK were targets of drugs for
SSc in any phase of clinical trial (i.e., abatacept and dasatinib,
respectively). We assessed the significance of the overlap and
found that our SSc target genes were significantly enriched in
pharmacological active targets for SSc (OR= 6.0; Fisher’s exact
test P= 4.7 × 10−2) (Supplementary Table 5).
Discussion
The large cohort of SSc included in the present study allowed us
to identify 13 new risk loci for the disease, almost doubling the
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Fig. 3 Tissue-specific enrichment for systemic sclerosis associations in
epigenetic marks. The heatmap displays the significant enrichment (p value
< 1.25 × 10−4) in 59 out of the 127 cell and tissue types in Roadmap
Epigenomics Consortium and the Encyclopedia of DNA Elements (ENCODE)
projects. The enrichment p values are plotted with different colors according
to the strength of the significance. Since the enrichments were computed at
various GWAS p value cutoffs (5 × 10−6, 5 × 10−7, 5 × 10−8), the most
significant p value was selected if a cell type/epigenetic mark combination
showed more than one significant enrichment across the different cutoffs.
Supplementary Data 13 provides the correspondence between cell codes and
cell types
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number of genome-wide association signals reported for SSc,
bringing the total number of SSc risk loci up to 28.
In the present study, some of the cohorts were genotyped using
different genotyping platforms between cases and controls. To
control for the potential spurious associations that this fact may
lead owing to the possibility of differential imputation quality for
the SNPs, we applied additional steps along with the standard QC
procedures. Prior to the imputation, we carefully excluded multi-
allelic, or A/T-C/G variants with MAF > 0.4 from all the data sets.
After imputation, we applied an in-house Perl script that com-
pares the genotypic frequencies between cases and controls and
excluded all SNPs showing genotypic inconsistencies. In addition,
manual inspection of the individual Manhattan plots from the 14
independent cohorts was performed and any suspicious false
positive signal was carefully analyzed and removed, if necessary.
In addition, the genome-wide significant signals identified in the
present study were the results of combining the effect of the
signals across several independent cohorts. Moreover, no sig-
nificant heterogeneity of the ORs was observed.
Applying a statistical fine-mapping approach, we reduced
associated signals to 95% credible sets of 10 likely causal SNPs or
fewer for 18 loci (72%). Notably, 95% credible sets comprised a
single variant in 6 loci (ARHGAP31, BLK, CD247, TNIP1, CSK,
STAT4-a). In other four loci, the credible sets contained two SNPs
(DGKQ, NUP85-GRB2, STAT4-b, IL12RB1). Functional annota-
tion of likely causal variants from credible sets revealed that all
variants with PPmax were intronic, intergenic, or ncRNA intronic
SNPs. These observations suggest that most of the genetic var-
iations underlying SSc susceptibility are related to transcriptional
regulatory mechanisms, including mRNA processing or stability
mediated by ncRNAs. Our results are in accordance with emer-
ging evidence that suggest a role of ncRNAs in autoimmunity34.
Moreover, the exonic nonsynonymous variants included in the
95% credible sets or in high LD to credible set SNPs did not show
clear evidence of being damaging mutations, as in the case of
CDHR5-rs2740375 located close to IRF7. As an exception, it is
worth mentioning that the nonsynonymous variant rs35677470
(R206C) in DNASE1L3, not present in our SNP panel, was
reported to impact the DNase activity of the encoded protein in
in vitro studies35. This fact is consistent with the result of our
statistical fine-mapping since the 95% credible set for this locus
was not well resolved (27 likely causal variants comprised the
credible set). Further functional studies will be needed to confirm
that rs35677470 (R206C) is the actual causal variant underlying
the association or whether there are secondary signals that also
influence the role of this genomic region in SSc susceptibility.
As expected, the results from gene expression data (eQTLs)
suggested that the functional role of certain SSc signals may
expand to several target genes. This hypothesis was confirmed
through the experimentally derived high-resolution maps of
enhancer-promoter interactions generated by H3K27ac HiChIP
in human CD4+ T cells. On average, HiChIP results found
physical interactions for approximately eight genes per SNP
across the 18 SSc likely causal variants that were mapped in the
H3K27ac HiChIP analysis, consistent with previous findings for
other ADs20. Strong interactions were observed in relation to
some SNPs. For example, CD247-rs2056626 (intronic SNP with
PPmax= 0.99 in the fine-mapping) showed a strong normalized
signal of HiChIP interaction to the CD247 promoter, suggesting
that the SNP affects an intronic regulatory element that controls
gene expression. This interaction between the SSc risk SNP and
the promoter of the CD247 gene in CD4+ T-cells was also
observed by the promoter capture Hi-C technique21,36, further
supporting that the SNP may be involved in the transcriptional
regulation of this gene. In fact, rs2056626 is a cis-eQTL for CD247
(p value= 2.411 × 10−48; FDR= 0) in whole blood.
The identification of target genes for GWAS signals is one of
the most challenging questions. In the present study, aggregate
analysis of chromatin interaction maps in a wide spectrum of
immune cell lines and eQTLs provided strong support to nomi-
nate 68 genes as robust SSc target genes (Table 3). Interestingly,
the function of some of these experimentally nominated
target genes are related to relevant pathways or biological pro-
cesses in SSc. For example, DDX6 encodes a RNA helicase
essential for efficient miRNA-induced gene silencing. De Vries
et al. demonstrated the role of DDX6 in the regulation of vascular
endothelial growth factor under hypoxic conditions37. Therefore,
this hit may establish a link between vasculopathy and SSc
unknown so far.
Other two new loci providing relevant mechanistic insights are
RAB2A and GSDMB. RAB2A belongs to the Rab family, a group
of membrane-bound proteins, involved in vesicular fusion and
trafficking. Specifically, RAB2A has been proposed to be a key
factor in autophagosome clearance38, thus it is another SSc risk
locus involved in autophagy apart from the previously described
ATG59. These results reinforce the role of autophagy in SSc
pathogenesis. In regard to GSDMB, it encodes a member of the
gasdermin-domain containing protein family. The functional
mechanism of gasdermin proteins is not clearly understood yet.
However, recent evidence demonstrated that some gasdermin-N
domains—including GSDMB—play a role in the induction of
pyroptosis39,40, an inflammatory form of cell death that is crucial
for the immune response. In line of these observations, our results
also suggest a role of defective pyroptosis in SSc.
Enrichment analyses of SSc loci in epigenetic marks of active
gene regulation showed a strong immune signature. We identified
relevant cell types and tissues for disease pathogenesis. Note-
worthy, primary NK cells represented one of the highest
enrichment signals across almost the entire panel. Our results are
consistent with previous reports linking NK cells to SSc41. In a
very recent publication, Benyamine et al.42 reported a particular
expression profile of NK cells in SSc and showed that this cell
type induced endothelial activation42. These findings may provide
a link between vascular damage and the immune imbalance
in SSc.
The inclusion of a wide panel of tissue and cell types captured
cell type-specific patterns of enrichment. For example, there were
some cell types that showed enrichment for a single histone mark.
It is important to note that these results add valuable information
to design future functional studies on the basis of accurately and
well-chosen cell types or tissues, thus increasing the rate of suc-
cess of the experiment.
Finally, it has been demonstrated that human genetic evidence
positively impacts the success rate in clinical development5. The
drug target enrichment found in the identified SSc target genes
supports that our results might also be informative in drug
repurposing. As an example, the present study supports the
possibility to consider ustekinumab for SSc treatment, which is a
drug currently approved for related diseases, such as psoriasis,
active psoriatic arthritis, and Crohn’s disease.
Methods
Study cohorts and GWAS quality control. This study included 14 independent
epidemiological cohorts comprising a total of 28,179 unrelated and genome-wide
genotyped individuals (9846 SSc) patients and 18,333 healthy controls), after
genotyping quality control (QC) steps. In brief, nine new SSc GWAS cohorts and
five previously published SSc GWAS cohorts7,8 of European ancestry were included
(Spain 1, Germany 1, The Netherlands 1, USA 1, France, Spain 2, Germany 2, The
Netherlands 2, USA 2, Italy, UK, Sweden, Norway and Australia/UK) (Supple-
mentary Table 1). SSc patients fulfilled the 1980 American College of Rheuma-
tology classification criteria for this disease or the criteria proposed by LeRoy and
Medsger for early-SSc43,44. In addition, patients were classified as having lcSSc or
dcSSc, as described in LeRoy et al.45 Patients were also subdivided by autoantibody
status according to the presence of ACA, ATA, or ARA autoantibodies. The main
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clinical features are shown in Supplementary Table 4. This study complied with all
relevant ethical regulations. CSIC’s Ethics Committee approved the study protocol,
and written informed consent was obtained in accordance with the tenets of the
Declaration of Helsinki.
Genome-wide genotyping was undertaken using the arrays specified in detail in
Supplementary Table 1. Stringent QC measures were applied to all GWAS data sets
as follows: SNPs with call rates < 0.98; minor allele frequencies (MAFs) < 0.01; and
those that deviated from Hardy-Weinberg equilibrium (HWE; p < 0.001 in both
case and control subjects) were filtered out from further analysis; samples with call
rates < 0.95 were removed. The presence of relatives and/or duplicates was assessed
by computing identity-by-descent (IBD) estimation using PLINK46. An individual
from each pair of relatives (Pi_Hat > 0.45) or duplicates (Pi_Hat > 0.99) was
removed. Additionally, duplicate/relatedness testing was also performed between
different GWAS data sets with the same country origin.
PC analysis and identification of outliers. To identify ancestry outliers, ~100,000
quality-filtered independent SNPs were selected from each case-control GWAS
cohort. PC analysis was performed using PLINK and GCTA64 and R-base software
under GNU Public license v.2. The first ten PCs per individual were calculated and
plotted. Samples showing > 4 standard deviations from the cluster centroids of each
cohort were considered outliers and removed from further analyses.
The total number of individuals that remained in the final filtered data sets after
this procedure was 26,679 (9095 SSc patients and 17,584 healthy controls).
Imputation. QC-filtered GWAS data sets were subjected to whole-genome geno-
type imputation using IMPUTE247 and the 1000 Genome Project Phase III
(1KGPh3) data as reference panel48. GTOOL was used to convert data sets into the
file format used by IMPUTE2. SNPs that were duplicated, multi-allelic, or A/T-C/G
with MAF > 0.4 were excluded. Imputation was done separately for each inde-
pendent study. A probability threshold of 0.9 was set for merging genotypes using
GTOOL. Imputed data sets were also QC-filtered by removing SNPs with call rates
< 0.98, with MAFs < 0.01 and those that deviated from HWE (p < 0.001). In
addition, singleton SNPs (which are not informative for phasing) and those that
showed genotypic inconsistency between cases and controls were also excluded
from analysis using an in house Perl script.
Genome-wide association analysis. Genome-wide association analyses were
performed in PLINK46 using a logistic regression model of additive effects,
including sex and the five first PCs as covariates in each of the 14 independent
European cohorts. Genomic inflation factor (λ) was calculated by cohort and
rescaled for an equivalent study of 1000 cases and 1000 controls when necessary
(λ1000). Quantile–quantile (Q–Q) plots were generated and plotted with an in
house R script to compare genome-wide distribution of the test statistic with
the expected null distribution (Supplementary Fig. 1). We conducted a fixed
effects inverse variance meta-analysis in PLINK46 to combine the ORs obtained
in each independent GWAS study. Heterogeneity values (I2 and Q) were cal-
culated with PLINK46 to evaluate possible OR heterogeneity across the 14
individuals cohorts. Novel signals of associations were defined as the genome-
wide significant associations (p value ≤ 5 × 10−8) that did not overlap with
previously SSc reported signals at the genome-wide significance level of
association.
Stratified analysis in clinical and serological SSc subtypes. Stratification of
patients according to SSc subtype (lcSSc, dcSSc) or autoantibody status (ACA,
ATA, and ARA) was performed to conduct stratified genome-wide association
analyses using the same procedure as for global analysis. All sub-analyses included
the 14 independent cohorts, with the exception of the GWAS analysis for ARA-
positive patients, which included Spain 2, USA 2, Italy, and UK cohorts according
to data availability.
Permutation analysis for subphenotype hits. A number of loci exhibited
stronger genetic signals in stratified analysis (lcSSc, dcSSc, ACA) as compared with
SSc as a whole despite the loss of statistical power caused by smaller numbers of the
subphenotypes. To investigate whether these outcomes could have occurred by
chance, we randomly shuffled 10,000 times a number of cases from each cohort
(while keeping controls constant) and reran association testing and subsequent
meta-analysis on the reshuffled data sets. The p values were converted to z scores to
generate a null distribution of this test statistic. In detail, for each subtype, the
number of cases randomly selected was determined by the prevalence of the
subtype observed in the present study: we selected 62.52% of cases for lcSSc,
27.75% for dcSSc, and 36.77% for ACA+. The empirical p value (p*) was calcu-
lated as the number of permuted z scores that were at least as extreme as the actual
z score+ 1 divided by the number of permutations+ 131.
Stepwise conditional analysis in SSc-associated loci. The presence of inde-
pendent signals in the genomic regions with significant signals in the meta-
analysis was assessed by joint conditional analysis by GCTA49. This method
uses summary-level statistics from meta-analysis and applies LD correction
between SNPs estimated from a reference sample set. Conditional analysis of
each associated locus was performed within a standard region of 1.5 Mb-win-
dow centered on the most associated SNP (index or lead SNP), with the
exception of DNASE1L3 region, where we explored the locus to 2 Mb owing to
the extent of the haplotype block. LD patterns were estimated using genotype
data from the 14 individual cohorts as reference. Conditional association ana-
lysis was performed including the lead SNP as covariate. Any SNP showing a
conditional association p value < 5 × 10−6 was considered as independent signal
and was further included in a new round of conditional analysis. This process
was repeated until no SNP with p value < 5 × 10−6 remained in any of the
genomic regions explored. The observed independent signals were confirmed
using PLINK46 by dependence analysis at cohort level scans through stepwise
logistic regression with adjustment for the most associated signals in each locus,
followed by inverse variance weighted meta-analysis under a fixed effects model.
Fine-mapping of SSc-associated loci in a Bayesian framework. After the
assessment of independent signals in significant loci from the meta-analysis,
statistical fine-mapping was carried out using PAINTOR (Probabilistic Anno-
tation INTegratOR) v3.050,51 searching for one causal SNP per independent
associated region. PAINTOR performs probabilistic inference and computes
posterior probabilities (PP) for SNPs to be casual considering the strength of
association (Z score) and the LD pattern across genomic regions. The association
strength was quantified using Wald statistic (“Equation (1)”) from ref. 50, and
the LD information was provided by a LD matrix containing pairwise Pearson
correlations coefficients between each SNP. In addition, PAINTOR leverages
functional annotation data as a prior probability to improve SNP prioritization.
Finally, the method uses Bayes theorem to obtain PP for SNPs to be casual,
which in turn were used to generate 95% credible sets (the smallest list of
variants that jointly have a probability of including the causal variant ≥ 95%).
Associated regions that contained more than one independent signal were split
to obtain regions containing only one independent signal by integrating local LD
information as well as the recombination rates using the online-tool LDlink
(https://ldlink.nci.nih.gov/)52.
The selection of functional annotations for PAINTOR fine-mapping was carried
out by stratified information enrichment calculations using GARFIELD25,26 (http://
www.ebi.ac.uk/birney-srv/GARFIELD/) (method explained in more detail in
‘Enrichment analysis of SSc risk loci in epigenetic marks and cell types’) with the
annotation panel distributed in GARFIELD package. The purpose was to
systematically select annotations relevant to SSc on the basis of functional
enrichment analysis. GARFIELD tests its robustness by calculating functional
enrichment for at least four significance cutoffs (p value < 1e −5/−6/−7/−8)
applied to the variants. GARFIELD analysis was carried out in our genome-wide
SNP panel by setting default parameters and omitting SNPs from chromosome 6
between Mb25 and Mb34. We determined a set of nine annotations to be used for
fine-mapping that showed: A significant enrichment (FDR < 0.05) of GWAS SNPs
for at least two out of the four significance cutoffs analyzed (p value < 1e −5/−6/
−7/−8); and b) A low inter-annotation correlation as suggested by PAINTOR
(median inter-annotation Pearson correlation < 0.35) (Supplementary Data 12).
Functional annotation of SNPs from credible sets. Functional characterization
of the SNPs included in credible sets was performed by assessing SNP functional
categories by means of wANNOVAR using default parameters53. Then we explored
overlap with eQTLs, epigenetic histone marks of active promoters and active
enhancers (H3K9ac, H3K4me1, and H3K27ac), and the presence of exonic non-
synonymous variants in high or moderate LD (r2 ≥ 0.8, r2 ≥ 0.6, respectively) using
HaploReg v4.154. For eQTL interrogation, we used blood eQTL from Westra
et al.55, the Geuvadis data set56—which contains expression data from lympho-
blastoid cell lines—and the Genotype–Tissue Expression (GTEx) project57—which
provides RNA sequencing-based eQTL for a wide range of human tissues. Overlap
of SNPs with chromatin marks was interrogated in selected cell lines from the
Roadmap Epigenomics Project15 (Supplementary Table 1). Cell lines were selected
according to the results of the functional enrichment analysis from ‘Enrichment
analysis of SSc risk loci in epigenetic marks and cell types’ for H3K9ac, H3K4me1,
and H3K27ac histone marks.
Finally, we assessed pleiotropic effect of our signals by determining whether the
SNPs included in the credible sets had been reported to be associated with other
ADs. For this, we interrogated the new NHGRI-EBI GWAS Catalog (https://www.
ebi.ac.uk/gwas/)58 through the web tool FUMA GWAS (http://fuma.ctglab.nl/)59.
H3K27ac HiChIP analysis in human CD4+ T cells. Experimentally derived high-
resolution maps of enhancer-promoter interactions generated by H3K27ac HiChIP
experiments20 were explored to identify target genes of SSc-associated variants.
HiChIP was developed by Mumbach et al.18 for the analysis of protein-directed
chromosome conformation in a very efficient and sensitive way. The H3K27ac
HiChIP experiments were performed by Mumbach et al. in human CD4+ T cells
from healthy donors: Primary human naïve T cells (CD4+CD45RA+CD25
−CD127hi), regulatory T (Treg) cells (CD4+CD25+CD127lo) and T helper 17
(Th17) cells (CD4+CD45RA−CD25−CD127hiCCR6+CXCR5−)20. Virtual 4 C
plots were generated from dumped matrices generated with Juicebox. The Juicebox
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tools dump command was used to extract the chromosome of interest from the.hic
file60,61. The interaction profile of a specific 5 kb or 10 kb bin containing the anchor
was then plotted in R. Replicate reproducibility was visualized with the mean
profile shown as a line and the shading surrounding the mean representing the
standard deviation between replicates. We explored chromatin interactions of the
most likely causal variants by setting as anchor points the SNPs with maximum
PPs in each of the independent associated loci. To identify the connectivity of
candidate SNPs to target genes, we called interactions by manual inspection of
individual SNP virtual 4 C interaction files and subset these interactions to those
containing a transcription start site and SNP18,20. Fit-Hi-C algorithm was used to
identify statistically significant (q value ≤ 1e-60) distance-matched enrichment of
interaction over background18,62.
The functional relevance of the H3K27ac HiChIP findings was further validated
by evaluating whether the explored SNPs were eQTLs for the HiChIP nominated
target genes.
Promoter capture Hi-C analysis. Chromatin interaction maps obtained by pro-
moter capture Hi-C experiments in a wide spectrum of immune cell types21,22 were
assessed using the web-based tool Capture Hi-C Plotter (CHiCP) (https://www.
chicp.org/)63. The SNPs with maximum PPs in each of the independent associated
loci were used as anchor points to explore physical interactions between restriction
fragments containing the variants and gene promoters.
Enrichment of SSc loci in epigenetic marks and cell types. To assess whether
our SSc GWAS SNPs were not randomly distributed among functional or
regulatory elements in the genome, we performed functional enrichment ana-
lysis of non-MHC SNPs using GARFIELD v2.025,26. This method estimates
enrichment of overlap on functional information computing ORs at various
GWAS p value cutoffs, and tests the significance of the enrichment under a
generalized linear model. GARFIELD accounts for major sources of con-
founding factors by incorporating high-LD proxies (r2 > 0.8), MAF, and tran-
scription start site distance as categorical covariates in the logistic regression
model. Enrichment was tested on independent SNPs after pruning of GWAS
SNPs (r2 > 0.1). We omitted SNPs of chromosome 6 between Mb25 and Mb34
to avoid bias.
GARFIELD provides an annotation panel that includes 1005 annotations
(genetic annotations, chromatin states, histone modifications, DNase I
hypersensitive sites and transcription factor binding sites in different cell lines)
from ENCODE, GENCODE and Roadmap Epigenomics projects15,24,64. Moreover,
GARFIELD can be run using a custom annotation panel. The second option was
selected for our enrichment analysis using annotations for 127 reference
epigenomes (Supplementary Data 13) and 9 epigenetic marks (H2BK20ac,
H3K27ac, H3K4me1, H3K4me2, H3K4me3, H3K9ac, H3K4ac, H3K79me1,
H2BK15ac) obtained from the Roadmap Epigenomics Consortium and the
Encyclopedia of DNA Elements (ENCODE) projects15,24. Annotations used were
Imputed Narrow Peaks as generated by the software Chrom-Impute65 and
obtained from https://egg2.wustl.edu/roadmap/data/byFileType/peaks/
consolidatedImputed/narrowPeak/. The estimated ORs were computed at various
GWAS p value cutoffs (5 × 10−6, 5 × 10−7, 5 × 10−8) and the R code Garfield-Meff-
Padj.R provided by GARFIELD was used to calculate an enrichment p value
threshold adjusted for multiple testing (P value= 1.25 × 10−4) on the effective
number of annotations (Meff= 400.4454).
Drug-target gene enrichment analysis. Target genes nominated in the present
study were used to query the Open Target Platform33 in order to assess whether
any of the genes encode proteins that are drug targets in any phase of clinical trial
(phase I–IV). Enrichment of overlap between SSc target genes with pharmacolo-
gical active targets for the diseases was calculated by Fisher’s exact test.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Summary statistics of the meta-GWAS analyzed in the current study will be made
available through the NHGRI-EBI GWAS Catalog (https://www.ebi.ac.uk/gwas/
downloads/summary-statistics) (please use ‘Systemic Sclerosis’ and/or ‘Lopez-Isac/
Martin’ as search terms). Individual-level genotype data are not publicly available owing
to them containing information that could compromise research participant privacy or
informed consent. All other data are contained in the article file and its supplementary
information or available upon reasonable request to the corresponding authors.
Epigenetic annotation panel used in this study were Imputed Narrow Peaks obtained
from https://egg2.wustl.edu/roadmap/data/byFileType/peaks/consolidatedImputed/
narrowPeak/.
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